

**SCPHARMACEUTICALS INC.**  
25 Burlington Mall Road, Suite 203  
Burlington, Massachusetts 01803

March 20, 2024

**Via EDGAR**

Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, DC 20549  
Attention: Daniel Crawford

Re: **scPharmaceuticals Inc.**  
**Registration Statement on Form S-3**  
**Filed March 13, 2024**  
**File No. 333-277886**

To the addressee set forth above:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, scPharmaceuticals Inc. (the “**Company**”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-277886) be accelerated by the Securities and Exchange Commission to 4:30 p.m. Washington D.C. time on March 22, 2024 or as soon as practicable thereafter.

The Company requests that we be notified of such effectiveness by a telephone call to Peter N. Handrinis of Latham & Watkins LLP at (617) 948-6060 or Wesley C. Holmes of Latham & Watkins LLP at (617) 948-6027 and that such effectiveness also be confirmed in writing.

Sincerely,

**scPharmaceuticals Inc.**

By: /s/ Rachael Nokes

Rachael Nokes  
Chief Financial Officer

cc: Peter N. Handrinis, Latham & Watkins LLP  
Wesley C. Holmes, Latham & Watkins LLP